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ABSTRACT
The cytosolic branched chain aminotransferase (BCATc) protein has been found to 
be highly expressed in breast cancer subtypes, including triple negative breast cancer 
(TNBC), compared with normal breast tissue. The catabolism of branched-chain amino 
acids (BCAAs) by BCATc leads to the production of glutamate and key metabolites 
which further drive the TCA cycle, important for cellular metabolism and growth. 
Upregulation of BCATc has been associated with increased cell proliferation, cell cycle 
progression and metastasis in several malignancies including breast, gliomas, ovarian 
and colorectal cancer but the underlying mechanisms are unclear. As nutrient levels 
of BCAAs, substrates of BCATc, regulate the PI3K/Akt pathway we hypothesized 
that increased expression of BCATc would contribute to tumour cell growth through 
upregulation of the insulin/IGF-1 signalling pathway. This pathway is known to 
potentiate proliferation and metastasis of malignant cells through the activation of 
PI3K/Akt and the RAS/ERK signalling cascades. Here we show that knockdown of 
BCATc significantly reduced insulin and IGF-1-mediated proliferation, migration and 
invasion of TNBC cells. An analysis of this pathway showed that when overexpressed 
BCATc regulates proliferation through the PI3K/Akt axis, whilst simultaneously 
attenuating the Ras/Erk pathway indicating that BCATc acts as a conduit between 
these two pathways. This ultimately led to an increase in FOXO3a, a key regulator 
of cell proliferation and Nrf2, which mediates redox homeostasis. Together this data 
indicates that BCATc regulates TNBC cell proliferation, migration and invasion through 
the IGF-1/insulin PI3K/Akt pathway, culminating in the upregulation of FOXO3a and 
Nrf2, pointing to a novel therapeutic target for breast cancer treatment.
INTRODUCTION
Triple negative breast cancer (TNBC) is the most 
aggressive subtype of breast cancer and is associated with 
a poor prognosis [1]. TNBC is defined by the absence of 
oestrogen and progesterone receptors and the absence of 
HER2 overexpression. There is a lack of targeted therapy 
for TNBC due to wide heterogeneity for this subtype, 
which contributes to increased drug resistance, virulence 
and difficult to treat nature [2]. A key event promoting 
tumour cell proliferation and migration is metabolic 
reprogramming, where in response to oncogenic signals 
increased nutrient supplies drive cancer progression [3]. 
Several pathways have been associated with tumour 
progression including the phosphoinositide-3 kinase 
(PI3K)/serine/threonine-specific protein kinase (Akt) and 
the Ras/extracellular-signal-related kinase (ERK) pathway 
(also known as the Ras-Raf-MEK-ERK pathway). These 
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pathways are controlled through the import of nutrients 
into cells by growth factors, such as insulin-like growth 
factor 1 (IGF-1), epidermal growth factor (EGF) and 
insulin, which mediate a cascade of events that regulate 
numerous cellular processes including cell growth and 
proliferation [4]. Upregulation of key signalling proteins 
of these pathways such as PI3K and ERK have been linked 
to several cancers including lung, thyroid and pancreatic 
cancer [5].
More recently the branched chain aminotransferase 
proteins (BCAT), which catalyse the transamination of the 
branched chain amino acids (BCAA), leucine, valine and 
isoleucine to their respective α-keto acids and glutamate 
(reviewed in [6]) have been identified as regulators of cell 
proliferation and migration [7, 8]. This cytosolic protein, 
BCATc, regulated by c-Myc, was found to be upregulated 
in a variety of cancers including gliomas [7, 9] ovarian, 
colorectal and breast [8, 10, 11]. The BCAA, particularly 
leucine, are potent nutrient signals and together with 
growth factors such as the IGFs and the hormone insulin 
regulate PI3K/Akt signalling [12]. Nutrient status is also 
sensed by the general control non-derepressible 2 kinase 
(GCN2) co-ordinates cell growth, proliferation and cell 
survival [13]. Therefore, by upregulating membrane 
transporters and nutrient uptake, cancer cells support the 
increased demand for macromolecules needed for cell 
growth [14].
Emerging evidence has indicated that the BCAT 
proteins, traditionally assigned metabolic roles, may have 
additional ‘moonlighting’ cellular functions, which are 
regulated through their peroxide sensitive-redox active 
CXXC motif [15]. We have recently established that the 
BCAT proteins can form thiol-dependent interactions with 
key signalling molecules such as those in the PI3K/Akt 
and the Ras/ERK pathways (unpublished observations) 
and show that phosphorylation of BCAT by PKC kinases 
is redox-dependent [16]. We showed that BCATc regulated 
autophagy through an interdependence of redox-regulated 
phosphorylation, supporting a ‘moonlighting’ role for this 
metabolic protein.
In this study, we show that BCATc regulates 
cross-talk between the PI3K/Akt and the Ras/ERK 
pathway. Using the TNBC cell model MDA-MB-231, 
we demonstrate that knockdown of BCATc results in 
a significant decrease of IGF-1 and insulin-mediated 
cell proliferation and migration. Subsequent analysis 
demonstrated that cell proliferation was associated with 
activation of the PI3K/Akt pathway that resulted in 
increased activation of FOXO3a, a transcription factor 
known to be involved in cell proliferation. Importantly, 
BCATc at the same time suppressed phosphorylation of 
ERK, indicating that regulation of proliferation through 
BCATc is primarly through the PI3K/Akt pathway rather 
than through ERK signalling, thus highlighting the 
plasticity of tumours to advance and adapt to changing 
environments.
RESULTS AND DISCUSSION
BCATc regulates proliferation, migration and 
invasion through the IGF-1 and insulin signalling 
pathway
Using siRNA we show that BCATc is intrinsically 
involved in mediating cell proliferation, migration and 
invasion of MDA-MB-231 cells (Figure 1A–1D). Similar 
studies have also reported a decrease in proliferation, 
metastasis and invasion of tumour cells in breast, colon and 
hepatocellular cancer in response to BCAT1 knockdown [8, 
11, 17]. The oncogene c-Myc not only upregulates BCAT1 
but transporters associated with glutamine and the neutral 
amino acid transporter 5 (SN5) [18]. Accumulation of 
glutamine and upregulation of glutaminase, which converts 
glutamine to glutamate, enhances glutathione synthesis, TCA 
cycle activation together with lipid and protein synthesis 
promoting cell growth and proliferation [19]. Moreover, 
leucine (a key substrate for BCAT), when restricted, has 
been shown to reduce cell proliferation, in several cancer 
cell lines including malignant melanoma (A375), lung 
cancer (A549), ovarian cancer (A2780) and breast cancer 
(MCF-7 and MDA-MB-231) [20] supporting a role for 
BCAA metabolism in regulating cell proliferation. Leucine 
together with glutamine is required for the activation of 
mTOR, as it relies on glutamine export for the intracellular 
transport of leucine through the bidirectional SLC7A5/
SLC3A2 transporter [21]. In acute lymphoblastic leukaemia 
(ALL) deletion of SLC7A5 (a high affinity transporter for 
glutamine) impaired T-cell tumour progression suggesting 
that several aspects of BCAA metabolism are important in 
regulating cell proliferation [22].
We next showed that the IGF-1 and insulin-mediated 
increase in proliferation and migration of MDA-MB-231 
cells was significantly attenuated by BCAT1 knockdown 
indicating that BCATc controls proliferation and migration 
through the IGF-1 and insulin pathway (Figure 2A–2C). 
This was also observed in the SKOV-3, ovarian cell 
line (Supplementary Figure 1A–1D). The IGF-1/insulin 
pathway facilitates an orchestrated activation of numerous 
cell signalling events initiated through phosphorylation 
of insulin receptor substrates (IRS1/2) [23]. Numerous 
studies support a role for this pathway in tumorigenesis 
(reviewed in [24]) with overexpression of key proteins 
such as the IGF-1 receptor tyrosine kinase reported in 
breast cancer [25]. Leucine signalling is intrinsically 
linked with insulin with a suggestion that plasma BCAA 
levels play a role in insulin-mediated regulation through 
the Akt/mTOR pathway (as reviewed by [26]).
BCATc significantly reduces IGF-1 mediated 
activation of ERK
Knockdown of BCATc led to a significant decrease 
in the levels of the IGF-1Rβ (Figure 3A and 3B). 
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Elevated levels of BCAA have been reported to inhibit 
the activation of IGF-1R [27], indicating that BCATc 
upregulation together with BCAA, allows activation of the 
IGF-1R signalling cascade. Activation of the IGF-1/insulin 
pathway triggers two predominant signalling pathways, 
the PI3K/Akt and Ras/ERK pathway. ERK proteins are 
central transducers of extracellular signals from hormones, 
growth factors, cytokines and environmental stress; they 
regulate many cellular processes throughout the cell and 
phosphorylate transcription factors, cytoskeletal proteins 
and other protein kinases and enzymes [28–30].
Recruitment and phosphorylation of insulin receptor 
substrate 1/2 (IRS1/2) via IGF-1 acting on its receptor 
activates the Src homology 2 domain-containing (Shc) 
protein, which was shown to be significantly increased 
in response to BCATc overexpression (Figure 3C). The 
Shc substrate binds to the adaptor protein growth factor 
receptor-bound 2 (Grb2), levels of which were unaffected 
by BCATc and the associated guanine nucleotide exchange 
protein, son of sevenless (SOS), that we showed was 
increased when BCATc was overexpressed (Figure 3D 
and 3E, respectively). Interestingly, Grb2 has been 
assigned a regulatory role in the activation of the Ras/
ERK pathway, through monomer/dimer interchange, that 
controls binding to SOS [31]. SOS allows the exchange 
of nucleotide guanosine diphosphate (GDP) bound to 
Ras with nucleotide guanosine triphosphate (GTP) in the 
cytosol. GTP-bound Ras allows membrane recruitment 
and activation of the serine/threonine protein kinase Raf to 
the plasma membrane [32]. Normally, this would enhance 
and activate mitogen-activated protein kinase (MAPK), 
which we expected to see in response to overexpression 
of BCAT. However, we show that knockdown of BCAT1 
increased phosphorylation of MAPK, even in the presence 
of IGF-1 or insulin and the opposite when BCATc was 
overexpressed (Figure 4A and 4B). Using confocal 
microscopy, we show that knockdown of BCAT1 increased 
MAPK translocation to the nucleus indicating that BCATc 
may play an important role as a chaperone or scaffold 
protein for MAPK (Figure 5), a role previously reported 
Figure 1: Knockdown of BCAT1 significantly reduces proliferation, migration and invasion of MDA-MB-231 cells. 
Cells were treated with 20 nM BCAT1 siRNA for 72 hours and the effect on proliferation assessed using the tritiated thymidine incorporation 
assay, migration was assessed using cells seeded onto 8 μm Transwell inserts (Greiner Bio-One) coated with collagen and after 24 hours, 
migrated were fixed and stained with 0.2% Crystal Violet, solubilised and absorbance measured and to assess invasion Matrigel added to 
the inserts as described above (A) Respective densitometric analysis of fold changes of protein expression relative to ɑ-tubulin are presented 
to the right of immunoblots. (B) Fold change in disintegrations per minute (DPM) and representative images of (C) migrated cells and (D) 
invaded cells with fold changes in absorbance at 590 nm ± SEM presented (n = 3) ***p < 0.001 and ****p < 0.0001 (scale bars = 100 μm).
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for BCATc [33]. This response was significantly increased 
in response to insulin, which will affect downstream 
nuclear and cytoplasmic targets.
We have previously shown that BCATc is 
phosphorylated through redox-regulated PKC 
activation [16]. The BCAT proteins also have various 
phosphorylation motifs for MAPK defined using the 
Motif Scan program (http://scansite.mit.edu) (Figure 6A), 
highlighting 3 structurally accessible consensus sequences 
for MAPK, T33, S188 and T278 (Figure 6B). We show 
that BCATc is a substrate for MAPK phosphorylation 
where the redox sensor is important for phosphorylation. 
Interestingly, we show that when both proteins are 
oxidised then MAPK-mediated phosphorylation of BCATc 
is enhanced (Figure 6C). Therefore, we propose that the 
association between MAPK and BCATc is controlled 
through redox regulated phosphorylation governed by 
insulin and redox signalling, such that under conditions 
that promote tumour growth, BCATc levels not only 
increase but a change in function from transaminase to 
chaperone occurs. We evidence that BCATc shows both 
positive and negative regulation of key proteins involved 
Figure 2: Knockdown of BCAT1 significantly reduces insulin and IGF-1-mediated migration of MDA-MB-231 cells. 
Cells were treated with 20 nM BCAT1 siRNA, 100 nM insulin and 100 ng/mL IGF-1 accordingly cell proliferation measured using the 
thymidine incorporation (TTI) assay and migration was assessed using cells seeded onto 8 μm Transwell inserts (Greiner Bio-One) coated 
with collagen and after 24 hours, migrated were fixed and stained with 0.2% Crystal Violet, solubilised and absorbance measured (A) 
Fold changes of mean values of disintegrations per minute (DPM) ± SEM, relative to control (B) Data presented as mean fold changes of 
absorbance at 590 nm. *p < 0.05, **p < 0.01 and ***p < 0.001 (C) Representative images of migrated cells (scale bars = 100 μm).
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Figure 3: Knockdown and overexpression of BCAT1 regulates IGF-1/insulin signalling cascade in MDA-MB-231 cells. 
Cells were treated with stable shRNA transfection for BCAT1 knockdown (BCAT1) and overexpression (BCATc) for 8 days. (A) Western 
blot analysis confirmed BCAT1 knockdown and overexpression. Western blot analysis was also used to assess changes in the protein 
expression of IGF-1 downstream targets (B) IGF-1Rβ (C) Shc (D) Grb2 (E) SOS. Respective densitometric analysis of fold changes of 
protein expression relative to ɑ-tubulin are presented. Data representative of mean ± SEM (n = 3) *p < 0.05, ***p < 0.001 and ****p < 0.0001.
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in the Ras/ERK pathway with the ultimate decrease in 
IGF-mediated activation of ERK, suggesting that BCATc-
induced regulation of cell proliferation and metastasis is 
unlikely to occur via this pathway.
BCATc regulates cross-talk between the Ras/
ERK and PI3K/Akt pathways
Since increased activation of MAPK in response to 
BCAT1 knockdown does not contribute to cell proliferation 
or migration, we next considered if these outcomes were 
through the PI3K/Akt signalling cascade. In response to 
IGF-1 and insulin signalling, overexpression of BCATc 
increased phosphorylation of Akt (Figure 7), whereas a 
significant increase in mammalian target of rapamycin 
(mTOR) was not reported (Supplementary Figure 2). 
Under normal cellular conditions, the metabolite 
α-ketoglutarate, the product of leucine transamination, 
activates mTOR. However, BCAT is regulated through 
phosphorylation and changes in the redox environment, 
which can prompt BCATc to associate with other 
signalling pathways, dependent on the stimuli, such 
as nutrient load, insulin/IGF-1 or changes in the redox 
environment [16]. Therefore, in response to IGF-1 or 
insulin the role of BCATc may switch from supporting 
mTOR activation to associate with proteins from the 
PI3K/Akt pathway. The dynamics and vectorality of these 
mechanisms are not entirely clear but more than likely 
Figure 4: Knockdown and overexpression of BCAT1 negatively regulates phosphorylation of MAPK in MDA-MB-231 
cells. Cells were treated with stable shRNA transfection for BCAT1 knockdown (BCAT1) and overexpression (BCATc) or unmodified 
pULTRA plasmid with no insertions as a control (Empty) for 8 days and treated with 100 nM insulin and 100 ng/mL IGF-1. (A) Western 
blot analysis was used to assess changes in the protein expression of phospho-MAPK and (B) MAPK. Respective densitometric analysis 
of fold changes of protein expression relative to ɑ-tubulin are presented below the immunoblots. Data representative of mean ± SEM (n = 
3) *p < 0.05, **p < 0.01 and ***p < 0.001.
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will involve redox-regulated phosphorylation, such as that 
described for BCATc.
As discussed above, the levels of Shc and SOS were 
increased in response to increased BCATc expression 
(Figure 3C and 3D). Whilst it is accepted that the 
activation of IGF-1Rβ, Shc, Grb2 and SOS leads to MAPK 
activation [34, 35], SOS can also activate Ras [36]. It is 
known that Ras, which is activated with increased SOS, 
can also activate PI3K, Rac and Rho proteins associated 
with the regulation of the cytoskeleton and invasiveness of 
tumour cells [37]. Shc has been demonstrated to increase 
Grb2 interaction with PI3K on the p85 regulatory subunit 
leading to activation of the catalytic subunit of p110 
[38, 39]. Moreover, Grb2 in a complex with the scaffolding 
protein Grb2-associated binder 1 (GAB) directly binds to 
p85 and enhances PI3K activation and subsequent Akt 
signalling [34, 40]. Thus, in this instance the increased 
level of these proteins may be associated with increased 
activation of the PI3K/Akt axis rather than increased 
activation of ERK.
Cross-talk of the RAS/ERK and PI3K/Akt pathways 
in the IGF-1/insulin signalling cascade allows tumour 
cells to utilise different effector molecules to promote 
tumour survival and progression (reviewed by [41]). One 
mechanism details that ERK phosphorylation of GAB1 
inhibits GAB-1-mediated membrane recruitment of PI3K 
which in turn leads to the suppression of Akt signalling 
[42]. On the other hand, at high doses of IGF-1, Akt 
phosphorylates RAF at Ser259 and thus suppresses the 
activity of the RAS/ERK signalling pathway [43, 44], 
which may be related to the role of BCATc. Downstream 
of the PI3K/Akt pathway, we found that the transcription 
factor forkhead box O3 (FOXO3a) was upregulated in 
response to BCATc overexpression and knockdown of 
BCAT1 led to reduced levels (Figure 7C). This effect 
was repeated in SKOV-3 cells (Supplementary Figure 
3A). This member of the FOXO subfamily of forkhead 
transcription factors, which mediate a variety of cellular 
processes including cell cycle progression and apoptosis 
[45]. The role of FOXO3a in breast cancer has been 
suggested to be ERα+-dependent whereby FOXO3a 
upregulation in ERα+ MCF-7 cells reduced cell migration, 
however, in TNBC MDA-MB-231 cells FOXO3a was 
found to promote tumour cell migration [46, 47]. FOXO3a 
can act on cyclin-dependent kinase inhibitor 1B (p27Kip1) 
directly by disrupting cyclin D/CDK4 and cyclin E/CDK2 
Figure 5: Insulin-mediated nuclear translocation of MAPK is significantly increased with BCAT1 knockdown in 
MDA-MB-231 cells. MDA-MB-231 cells were cultured on sterile glass coverslips (treated with poly-L-lysine) and treated with 20 nM 
BCAT1 siRNA, 100 nM insulin and 100 ng/mL IGF-1. Cells were fixed with 4% paraformaldehyde and permeabilised with Triton ×. (A) 
Immunofluorescence Z stacked images of MDA-MB-231 cells probed with anti-MAPK (1:100) overnight at 4C, and then anti-rabbit Alexa 
Fluor® 568 (1:250) for 1.5 hours. The coverslips were then mounted in VECTASHIELD HardSet antifade mounting medium with DAPI 
and imaged using a Leica SP8 confocal microscope. (B) Respective velocity analysis of Mander’s coefficient as compared to control. Data 
representative of mean ± SEM (n = 3) *p < 0.05 and ***p < 0.001. Blue - DAPI; Red - MAPK.
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complexes to promote cell proliferation [48]. Therefore, 
positive regulation of this transcription factor by BCATc in 
TNBC may contribute to BCATc-mediated proliferation, 
migration and invasion. IGF-1R signalling and subsequent 
Akt phosphorylation of FOXO3a leads to its translocation 
from nucleus to cytoplasm, where it associates with 
14.3.3 protein [49]. The 14.3.3 proteins act as scaffolds 
to integrate signalling proteins with targets involved in 
biological processes, including cell cycle regulation [50]. 
Interestingly, BCATc also has predicted binding motifs 
for Akt and 14-3-3 phosphorylation (Figure 6A), which 
like ERK may be the site of regulation for the interaction 
of these proteins. Overexpression of 14-3-3z has been 
associated with breast cancer recurrence indicating a role 
in therapy resistance, mediated via the downregulation of 
the pro-apoptotic proteins Bcl-2-associated death promoter 
(BAD) and Bcl-2-like protein (BIM) [51, 52]. Knockdown 
of BCAT1 was found to increase the percentage of cells 
in the early apoptotic stage and reduce the percentage 
of live cells (Figure 8A and 8B), indicating that BCATc 
expression allows TNBC cells to evade apoptosis. The 
underlying mechanism by which hBCATc regulates cell 
apoptosis has not yet been elucidated. Hence, regulation 
of these Akt downstream effector proteins indicates an 
intrinsic role for BCATc for tumour progression mediated 
by cell proliferation, migration, cell cycle control and 
evasion of apoptosis through the regulation of FOXO3a.
BCATc regulates cellular redox
We were interested to further elucidate the role of 
BCATc for tumour cell survival as increased glutamate 
Figure 6: Putative phosphorylation sites for BCAT and its interaction with ERK (A) The BCAT protein sequence (accession #) was 
analysed using the Motif Scan program, Scansite 4 (http://scansite.mit.edu). Putative Akt and ERK1/2 phosphorylation sites on BCAT, 
as well as regions conforming to the ERK1/2 D-recognition site (DRS) substrate docking site (ERK-DD) and 14-3-3 phosphoamino-acid 
binding motif (14-3-3) are shown. (B) Phospho-Thr residues (TPO) and Phospho-Ser (SEP) were mapped onto the BCATc structure (PDB 
ID: BCAT) using UCSF Chimera. Putative phosphosites (S188, T33 and T278) are shown in the surface display (left) and ribbon display 
(right). The redox center of BCAT, which is composed of C335 and C338, is shown in the circle. Likewise, the predicted DRS binding 
site on BCATc is labelled red. (C) H2O2 titration curves of phosphorylation of BCATc by ERK2. ERK2 and BCATc were either both pre-
treated with the indicated concentrations of H2O2 for 10 min at room temperature (orange) or only BCAT was pre-treated (blue). Excess 
H2O2 was then scavenged by catalase and the enzymes were combined in reaction buffer and incubated at 30°C for 30 min. The extent of 
phosphorylation was measured using the ADP-Glo assay. All activities were background corrected and normalized to that of the untreated 
controls. Error bars represent standard error (n = 6 for each dataset; *p < 0.05, **p < 0.01 and ***p < 0.001 relative to the untreated control).
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levels contribute to glutathione (GSH) biosynthesis 
by facilitating the uptake of cystine via the xc-cysteine 
transporter, which is coupled to the efflux of glutamate 
[53]. GSH plays an important role in redox homeostasis 
and tumour cell survival by protecting cells from 
damage caused by reactive oxygen species (ROS) 
generated during oxidative stress [19]. Redox status 
is predominantly regulated by the transcription factor 
nuclear factor erythroid 2-related factor 2 (Nrf2) and its 
repressor protein kelch-like ECH-associated protein 1 
Figure 7: Knockdown and overexpression of BCAT1 regulates the PI3K/Akt axis in MDA-MB-231 cells. Cells were 
treated with stable shRNA transfection for BCAT1 knockdown (BCAT1) and overexpression (BCATc) or unmodified pULTRA plasmid 
with no insertions as a control (Empty) for 8 days and treated with 100 nM insulin and 100 ng/mL IGF-1. (A) Western blot analysis was used 
to assess changes in the protein expression of phospho-Akt (B) Akt and (C) FOXO3a. Respective densitometric analysis of fold changes 
of protein expression relative to ɑ-tubulin are presented below the immunoblots. Data representative of mean ± SEM (n = 3) *p < 0.05 and 
**p < 0.01.
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(Keap1) in response to redox cellular status [54]. PI3K/
Akt activation is essential for the nuclear translocation of 
Nrf2, whereby Akt inhibitors, but not MAPK inhibitors, 
were found to reduce Nrf2 transcriptional activation of 
antioxidant genes [55]. Akt can also increase the stability 
of Nrf2 by activating p21 which disrupts the interaction 
between Keap1 and Nrf2, reducing Nrf2 phosphorylation, 
thereby preventing its nuclear export and ubiquitination 
[56]. Under low concentrations of ROS, Nrf2 is bound to 
the E3 ubiquitin ligase Keap1 in the cytosol and degraded 
by the proteasome [57]. In response to oxidative stress, 
this interaction is inhibited, by the oxidation of cysteine 
residues on Keap1, thus allowing Nrf2 translocation to the 
nucleus to induce the expression of antioxidant genes such 
as the oxidoreductases, thioredoxin (Trx) and glutaredoxin 
(Grx) [58]. Here, levels of Nrf2 were increased with 
BCATc overexpression and decreased with knockdown 
of BCAT1 (Figure 8C), suggesting that levels of BCATc 
positively regulate Nrf2 expression. Knockdown of 
BCAT1 also showed a decreased expression of Nrf2 
in SKOV-3 cells, which resulted in an increase in 
ROS (Supplementary Figure 3B). Nrf2 modulates the 
expression of oxidoreductases, thioredoxin (Trx) and 
glutaredoxin (Grx) which are important in regulating 
cellular redox state [58]. Trx is a pro-oxidant with anti-
apoptotic effects, including inactivation of caspase-3 [59], 
a primary player in the apoptotic signalling pathway, via 
a redox reactive nitrosothiol transfer [60]. Similarly, Grx1 
inhibits apoptosis through Akt activation [61]. Therefore, 
whilst the role of BCATc mediates tumour survival by 
activating IGF-1/insulin PI3K/AKT signalling pathway, 
its expression may also influence Nrf2 regulation of the 
cellular redox state.
Summary
IGF-1 is secreted by the liver in response to 
growth hormone, and its circulating levels remain 
constant via its unique interaction with its IGF binding 
proteins (IGFBPs). Unlike insulin, IGFs are also made 
in most cells of the body, where they play a key role 
in growth, survival and metabolism and are upregulated 
during cancer development. Insulin and IGF-1 are 
intricately linked systemically, for example during an 
insulin-resistant state the usual normalising processes 
are inhibited, leading to increased levels of circulating 
insulin and glucose. It also leads to a stimulation of 
hepatic IGF-1 synthesis, and downregulation of IGFBP-1 
and IGFBP-2, resulting in an increased bioavailability 
of IGF-1. The high circulating insulin and IGFs, in 
an insulin-resistant state, is thought to be one of the 
mechanisms underlying the link between disturbed 
metabolism and cancer progression.
Deregulation of nutrient signalling that affects 
the PI3K/Akt and Ras/ERK pathways potentiates 
proliferation and metastasis of malignant cells including 
breast cancer [5]. Our findings suggest that BCATc 
behaves as a molecular chaperone or molecular scaffold 
that influences cell survival through the regulation and 
crosstalk of several key pathways. We have shown 
BCATc to increase activation of the IGF-1R signalling 
cascade with subsequent activation of the PI3K/Akt 
axis whilst subsequently down-regulating the RAS/
ERK pathway. Moreover, BCATc promoted tumour 
cell survival through evasion of apoptosis mediated 
potentially through regulation of the redox status of the 
cells. In summary, BCATc provides TNBC cells with 
metabolic plasticity to alter dependence on the RAS/ERK 
and PI3K/Akt signalling cascades, in response to IGF-
1/insulin, to promote tumour survival and progression 
(Figure 9).
MATERIALS AND METHODS
Contact of reagent and resource sharing
Further information and requests for resources and 
reagents should be directed to and will be fulfilled by the 
Lead Contact, Prof. Myra Conway (myra.conway@uwe. 
ac.uk).
Experimental model and subject details
Cell lines and cell culture
MDA-MB-231 (triple negative breast cancer) 
were purchased from ATCC and cultured in Dulbecco’s 
Modified Eagle’s medium (DMEM) containing 10% foetal 
bovine serum (FBS) in a humidified incubator with 5% 
CO2 at 37°C.
Method details
siRNA transfection
The siRNA sequences for BCAT1 (Sense 
5′CAUUAUCUACUGCUUCACAUU and antisense 5′ 
UGUGAAGCAGUAGAUAAUGUU) were previously 
designed and validated by Dr. Tom Forshaw (primers 
were synthesised by Eurofins Genomics, Germany). 
Cells were transfected with 20 nM BCAT1 siRNA using 
Lipofectamine RNAimax or transfection solution prepared 
in Opti-MEM for 72 hours (Invitrogen, Paisley, UK).
Lentiviral shRNA transfection
The pULTRA-BCAT1 plasmids were prepared. In 
brief, an H1 promoter-BCAT1 shRNA sequence cassette 
was assembled in the pSUPER plasmid (VEC-PBS-0002, 
Oligoengine, Seattle, WA, a kind gift by Dr. Tim Craig) by 
ligation into the BglII and XhoI restriction sites. This was 
then amplified by PCR and the new plasmid assembled 
by ligation into the SnaBI restriction site of the pULTRA 
lentiviral vector (Addgene 24127, Cambridge, MA). For 
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overexpression of BCAT1, the human gene was PCR 
amplified from our pET28a (Novagen, Madison, WI) 
bacterial overexpression vectors (Davoodi et al., 1998) 
and the plasmid assembled by ligation into the BamHI and 
EcoRI restriction sites of pULTRA. Unmodified pULTRA 
plasmid with no insertions was included as a control. 
The pULTRA vector design included enhanced green 
fluorescent protein (GFP) expression, which was used to 
confirm uptake of the plasmid into transfected cells.
Lentiviral particles were produced by co-
transfection of Sigma Mission lentiviral packaging 
mix to manufacturers guidelines and the respective 
pULTRA plasmid into HEK293T cells using the PEI 
method (PMC4246624) and supplementation of viral 
media with 1 mM sodium butyrate to enhance viral yield 
(PMC3830501/). The lentiviral particles were harvested 
48 hours and 72 hours post-transfection of the HEK293T 
cells. For viral transfection of the MDA-MB-231 cells, 
harvested lentiviral particles were incubated with the cells 
for at least 8 days. To improve transfection efficiency 8 
μg/mL polybrene was added to the shRNA transfected 
cells. Transfection efficiency was assessed by fluorescent 
microscopy as indicated by GFP activation.
Western blot analysis
Cultured cells were lysed with radioimmune 
precipitation assay (RIPA) buffer supplemented with 
Figure 8: BCAT1 promotes tumour cell survival by evasion of apoptosis. Cells were treated with 20 nM BCAT1 siRNA 
for 72 hours or transfection control, and cell apoptosis was determined by FITC-Annexin V and propidium iodide staining using flow 
cytometry. (A) Representative flow cytometric analysis (B) Data representative of mean ± SEM (n = 3) *p < 0.05 and **p < 0.01 (C) Western 
blot analysis was used to assess changes in the protein expression of Nrf2. Respective densitometric analysis of fold changes of protein 
expression relative to ɑ-tubulin are presented. Data representative of mean ± SEM (n = 3) *p < 0.05 and **p < 0.01.
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protease inhibitor and the protein concentration for each 
sample determined by Bradford assay. Aliquots of cell 
lysates (20 µg of protein) were resuspended in NuPAGE® 
LDS (4% β-mercaptoethanol) and denatured at 95°C for 
10 minutes. Proteins samples were separated on a 4–12% 
polyacrylamide gel and transferred onto activated (100% 
methanol) PVDF membrane. Membrane was blocked with 
5% milk in TBST (50 mM Tris-HCl, 150 mM NaCl, 0.1% 
Tween-20) for 1 hour, washed with TBST, and incubated 
with appropriate primary antibodies overnight at 4°C. Next, 
membranes were washed with TBST and incubated with an 
appropriate secondary antibody at room temperature for 1 
hour. Luminata Forte ECL solution was used to visualise the 
bands using the Li-Cor Odyssey system and densitometric 
analysis preformed using IMAGE STUDIO Lite software.
3H thymidine incorporation proliferation assay
Radioactively labelled (tritium) thymidine was used 
to measure the proliferation of MDA-MB-231 cells by the 
incorporation of [3H] thymidine into the DNA of dividing 
cells. Cells were seeded at a seeding density of 2 × 104 cells 
in 24 well plates. Following treatment, cells were labelled 
with 0.1 µCi [3H] thymidine per well, incubated with 
5% trichloroacetic acid at 4°C for 10 minutes, followed 
by a 1 hour incubation with 1 M sodium hydroxide. The 
resulting suspension was added to a vial containing 2 mL 
ultima gold liquid scintillation cocktail (Perkin Elmer 
Beaconsfield, Bucks, UK) and incorporated counts were 
measured using a Beckman Scintillation Counter LS6500. 
Data were recorded as disintegrations per minute (DPM).
Migration and invasion assay
Thincert™ cell culture inserts (8 μm) (Greiner 
Bio-One) were coated with 10 μg/ml Collagen-I to 
measure migration and Matrigel® to assess invasion 24 
hours prior to cell seeding at room temperature. Cells 
were seeded in the upper chambers of the inserts at a 
density of 1 × 105 MDA-MB-231 cells/mL in serum-
Figure 9: The role of BCATc on the insulin/IGF-1 signalling cascades. Activation of IGF-1R and insulin receptor, mediated by 
ligand binding of IGF-1 or insulin leads to the subsequent activation of the PI3K/AKT pathways and the Ras/MAPK pathways. Increased 
expression of BCATc increased levels of IGF-1Rβ, Shc and SOS however MAPK activation was increased with knockdown of BCAT1 
suggesting BCATc inhibits MAPK activation. Increased levels of hBCATc increased phosphorylation of Akt and the expression levels of 
the downstream effector proteins; FOXO3a, and Nrf2 thereby promoting cell proliferation, migration, and evasion of apoptosis in TNBC.
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free DMEM and 10% FBS DMEM placed in the lower 
chambers, in a humidified incubator at 37°C with 5% 
CO2. Following 24 hours, cells on the upper surface of 
the membrane were removed using an ethanol coated 
cotton swab and cells on the lower chamber fixed in 
4% paraformaldehyde and stained with 0.2% Crystal 
Violet (Sigma). For each insert, representative images 
in 3 evenly distributed ×40 fields of view were captured 
using a light microscope (Zeiss AX10). To quantify 
migration and invasion of cells, 0.1% SDS in PBS 
was added to the lower chambers for 1 hour at room 
temperature and absorbance intensity measured on a 
plate reader at an excitation of 590 nm.
ERK2 activation and purification
Activated doubly-phosphorylated MAPK1/ERK2 
(pERK2) was generated and purified essentially as 
described by [62]. Briefly, 5× ATP solution (50 mM 
HEPES-KOH pH 7.38, 100 mM MgCl2, 20 mM DTT, 20 
mM ATP) and dilution buffer (10 mM HEPES-KOH pH 
7.38, 0.1% BME, 0.01% Triton X-100) were combined 
in a 1:4 ratio for a final volume of 25 mL. Inactive ERK2 
and constitutively active MEK1 were then added to the 
solution before the reaction mix was divided into 0.5 
mL aliquots. Reactions were then incubated at 30°C for 
60 min. The solution was then dialyzed against ERK2 
dialysis buffer (20 mM Tris-HCl, pH 8, 1 mM DTT) at 
4°C overnight. Dialyzed ERK2 was purified by 1 mL 
HiTrap Q HP anion exchange column (GE Healthcare) 
that was preequilibrated with equilibration buffer (20 
mM Tris-HCl, pH 8.0, 1 mM DTT, 0.1 M KCl, 10% 
glycerol). The reaction mix was then loaded onto the 
column and the column was washed with buffer A (20 
mM Tris-HCl (pH 8.0), 1 mM DTT, 10% glycerol) with 
a step gradient of buffer A supplemented with 0 to 0.3 
M KCl. Immobilized pERK2 eluted at about 0.2 M 
KCl. To assess the purity of the products, each fraction 
was resolved on a 5/10% SDS-PAGE gel and stained 
with Simply Blue Coomasie reagent. To determine 
which elution fractions contained the most protein, a 
Bradford total protein assay was completed. Briefly, 
elution fractions were assayed on a 96-well plate and 
incubated with Coomassie brilliant blue G-250 dye for 
10 min at room temperature. Absorbance (595 nm) was 
measured using a TECAN Infinite F500 Pro microplate 
reader and negative control readings were subtracted 
from all readings to obtain background-corrected values. 
Likewise, the activity of each pERK2 fraction was 
determined by in vitro kinase assays, as described below, 
using the modular ERK2 peptide substrate, Sub-D. 
Fractions containing active pERK2 were pooled and then 
concentrated using an Amicon Ultra-15 (30K MWCO) 
before being dialyzed into ERK2 storage buffer (20 mM 
Tris-HCl, pH 8.0, 1 mM DTT, 1 mM EDTA, 0.2 M KCl, 
10% glycerol) overnight at 4°C.
H2O2-dependent oxidation of pERK2 and BCAT
pERK2 and the BCAT isoforms was diluted to 
concentrations of 465 nM and 2 μM, respectively. The 
proteins were then treated with various concentrations 
of H2O2 (0–5 μM) and incubated for 10 minutes at room 
temperature. Untreated controls were incubated with diH2O 
in place of H2O2. The remaining H2O2 was then scavenged 
by one-minute exposure to catalase (2.5 units). Next, 2.5 
µL of pERK2 (treated and untreated) was incubated with 
2.5 µL 4× kinase reaction buffer (8 mM MOPS, pH 7.2, 
4 mM Beta-glyc-phosphate, 20 µM ATP, 8 mM MgCl2, 
1.6 mM EGTA, 0.64 mM EDTA, 64 ng/µL BSA) and 5 
µL of BCAT substrate (treated and untreated) at 30°C for 
30 minutes. Negative control reactions contained 2.5 µL 
of diH2O in place of active ERK2. Following the 30°C 
incubation, the ERK2 selective inhibitor, SCH772984, 
was added to the reaction to quench the reaction. The 
effects of H2O2 on pERK2’s ability to phosphorylate the 
BCAT isoforms was then detected using the ADP Glo® 
chemiluminescent kinase assay (Promega, Madison, WI) 
according to the manufacturer’s protocol. Briefly, the trans-
phosphorylation reaction (10 μL) was transferred into a 96-
well plate (Greiner, solid white, low-binding assay plates) 
and 10 µL of ADP Glo reagent was added to each well. The 
reaction was then incubated at room temperature for 40 min 
to deplete all remaining ATP [63]. The ADP produced by 
the enzyme/substrate interaction was then converted to ATP 
by adding 20 µL/well of Kinase Detection Reagent to yield 
a total assay volume of 40 µL/well. After the addition of 
Kinase Detection Reagent, the total reaction was incubated 
for 40 min and luminescence was detected with the TECAN 
Infinite F500-PRO microplate reader. Untreated controls 
received TBS vehicle at the same volume.
DCFDA – ROS assay
To evaluate the effect of BCAT1 on the generation 
of ROS, BCAT1-siRNA (20 nM) transfected SKOV-3 cells 
were seeded overnight. Here, cells were treated with 100 
µL of 2× 30 µM DCFDA solution and incubated in the 
dark at 37°C for 45 minutes. The fluorescent intensity was 
then measured on a fluorescence plate reader at excitation 
of 485 nm and emission of 535 nm.
Apoptosis assay
To determine the effect of BCAT1 siRNA 
knockdown on cell apoptosis, MDA-MB-231 cells were 
seeded at a density of 1 × 106 cells per T-25 flask and 
treated with 20 nM BCAT1 siRNA for 72 hours. Cells 
were detached and washed twice with ice cold PBS 
and resuspended in 1× binding buffer. Annexin V-FITC 
(Biolegend, San Diego) and PI (Fisher-Scientific) were 
added into the binding buffer and incubated for 10 min at 
room temperature in the dark. Analysis was performed on 
Oncotarget1984www.oncotarget.com
a BD Accuri™ C6 Flow Cytometer (BD Biosciences) to 
identify the subpopulations of the apoptotic cells.
Statistical analysis
All data were expressed as means ± standard error 
of the mean (SEM). Significance levels for comparisons 
between groups were determined with unpaired two-
tailed Student’s t-test using GraphPad Prism 8 (GraphPad 
Software). P values of < 0.05 were considered statistically 
significant. For Western blots, protein levels were 
normalised to α-tubulin and relative band density reported 
as a fold change to control.
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